Recent

% | $
Quotes you view appear here for quick access.

AVEO Pharmaceuticals, Inc. Message Board

arodbronx 5 posts  |  Last Activity: Jun 26, 2015 8:43 PM Member since: Aug 3, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • arodbronx arodbronx Jun 26, 2015 8:43 PM Flag

    Lots of dim bulbs posting on this board. All buyers of the offering have been disclosed by Arca in SEC filings.

    Venrock Healthcare Capital Partners II, L.P. 5,373,623
    VHCP Co-Investment Holdings II, LLC 2,178,904
    Venrock Healthcare Capital Partners, L.P. 2,736,388
    VHCP Co-Investment Holdings, LLC 500,409
    Growth Equity Opportunities Fund IV, LLC 10,221,465
    Franklin Biotechnology Discovery Fund 3,346,547
    Franklin Templeton Investment Funds 5,171,341
    RA Capital Healthcare Fund, L.P. 4,673,481
    Blackwell Partners LLC – Series A 1,005,111
    Tekla Life Sciences Investors 5,678,592
    Capital Ventures International 567,859
    DAFNA LifeScience L.P. 323,680
    DAFNA LifeScience Market Neutral L.P. 22,714

  • ABIO investors from the most recent SEC filing:

    Venrock Healthcare Capital Partners II, L.P. 5,373,623
    VHCP Co-Investment Holdings II, LLC 2,178,904
    Venrock Healthcare Capital Partners, L.P. 2,736,388
    VHCP Co-Investment Holdings, LLC 500,409
    Growth Equity Opportunities Fund IV, LLC 10,221,465
    Franklin Biotechnology Discovery Fund 3,346,547
    Franklin Templeton Investment Funds 5,171,341
    RA Capital Healthcare Fund, L.P. 4,673,481
    Blackwell Partners LLC – Series A 1,005,111
    Tekla Life Sciences Investors 5,678,592
    Capital Ventures International 567,859
    DAFNA LifeScience L.P. 323,680
    DAFNA LifeScience Market Neutral L.P. 22,714

    The first four on the list are all part of Venrock, one of the most successful venture capital firms in history: 10,221,465 shares.
    The next, Growth Equities Opportunities Fund, is part of New Enterprise Associates, also one of the most success venture capital firms in US history: 10,221,465 shares.
    Franklin funds: 8,517,888 shares.
    RA Capital needs no introduction. They're one of the most famous biotech investors, even more successful than Baker Brothers: 4,673,481 shares.
    Blackwell Partners: 1,005,111 shares
    Tekla Life Sciences Investors is a closed-end investment fund traded on the NYSE:5,678,592 shares.
    Capital Ventures International: 567,859 shares.
    DAFNA invests in publicly traded biotechnology: 346, 394 shares.

  • arodbronx arodbronx Jun 14, 2015 8:12 AM Flag

    Drugs often have multiple designation. Janssen/Pharmacyclic’s ibrutinib (Imbruvica) has five: Orphan Drug, Fast Track, Breakthrough, Priority Review and Accellerated Approval. Google this: Novel and New Drugs 2014 Summary - Food and Drug Administration. The first result should be a PDF file. Click on it and scroll down to page 13. It will show you all the drugs approved by FDA’s CDER division in 2014 and the multiple designations each has.

  • Reply to

    Adam Feuerstein what a **** imo

    by fuqww May 20, 2015 11:44 AM
    arodbronx arodbronx May 20, 2015 12:14 PM Flag

    For Adam’s benefit, the 20017 imetelstat NDA fling will be accomplished as follows:

    Phase II trial in relapsed/refractory myelofibrosis.
    Breakthrough Therapy Designation and accelerated approval filing under Suppart-H.
    Approval in myelofibrosis as second-line treatment.

    Once approved, Janssen will then run a head-to-head trial pitting imetelstat directly against ruxolitinib (Jakafi). Success will allow them to file for label expansion allowing iimetelstat to be marketed as frontline treatment.
    Look at the J&J slides released today. The timelines and writing are on the wall. Janssen’s plan is to ultimately make imetelstat the frontline treatment of choice in myelofibrosis. Anyone holding INCY should take note.

  • NTB-A is a CD2-related cell surface protein expressed primarily on lymphoid cells including B-lymphocytes from chronic lymphocytic leukaemia (CLL) and lymphoma patients. We have generated a series of monoclonal antibodies (mAbs) against NTB-A and assessed their therapeutic potential for CLL. Selective mAbs to NTB-A were further tested in functional complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicty (ADCC) assays in cell lines and B lymphocytes freshly isolated from CLL patients. While lower levels of NTB-A were detected in T and natural killer (NK) cells, CDC activity was demonstrated primarily in B cells isolated from CLL patients and B lymphoma cell lines. Knockdown of NTB-A by small interfering RNA in target cells results in lower cytotoxicity, demonstrating the specificity of the mAbs. Furthermore, anti NTB-A mAbs demonstrated anti-tumour activity against CA46 human lymphoma xenografts in nude mice and against systemically disseminated Raji human lymphoma cells in severe combined immunodeficient mice. Taken together, these results demonstrate NTB-A as a potential new target for immunotherapy of leukaemia and lymphomas.

AVEO
1.72-0.02(-1.15%)Jul 1 4:00 PMEDT